Integrative molecular navigator in preventable diseases: Pulmonary arterial hypertension (PAH) and rare diseases

Mukesh Kataria; Bonnie Welch; Diane E Heck; Hong Duck Kim

doi:10.30574/gscbps.2020.12.3.0285

Authors

Mukesh Kataria Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla NY.
Bonnie Welch Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla NY.
Diane E Heck Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla NY.
Hong Duck Kim Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla NY.

DOI:

https://doi.org/10.30574/gscbps.2020.12.3.0285

Keywords:

Pulmonary arterial hypertension (PAH) metabolomics, Polymorphism, Pharmacogenomics, Drug safety, Gene editing

Abstract

Pulmonary arterial hypertension (PAH) is a debilitating lung condition for which there has been no cure that leads to complications on the right side of the heart. This disorder is currently distinguished from other conditions of the right ventricle by a DNA biorepository, invasive hemodynamics, echocardiography, genotype-tissue expression, imaging, and other diagnostic tools. Present treatment strategies include mainly medications and oxygen therapy choices. Advanced omics developments, including next generational genetic analysis, massively parallel gene-editing, metabolomics, and pharmacogenomics have significantly improved the volume of information that can be analyzed effectively in individuals with pulmonary arterial high blood pressure among other chronic illnesses. Emerging molecular-driven and gene targeting-driven evidence shed light on a new era of innovation as advanced clinical technology for providing patients quality of care in case of systemic arterial morbidity recognition, early diagnosis, therapeutic validation, and safety, including precision treatments based on patients’ genomic data pool obtained through genetic imprinting or genetic mapping.

Metrics

Metrics Loading ...

References

Hemnes AR. Using omics to understand and treat pulmonary vascular disease. Frontiers in Medicine. 2018; 5, 157.

Chen D, Zhao X, Sui Z, Niu H, Chen L, Hu C, Xuan Q, Hou X, Zhang R, Zhou L, Li Y, Yuan H, Zhang Y, Wu J, Zhang L, Wu R, Piao H-L, Xu G, Jia W. A multi-omics investigation of the molecular characteristics and classification of six metabolic syndrome relevant diseases. Theranostics. 2020; 10(5): 2029-2046.

Teruel M, Chamberlain C, Alarcón-Riquelme ME. Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases. Rheumatology. 2017; 56(suppl_1): i78-i87.

Sun YV, Hu YJ. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. In Advances in genetics. 2016; 93: 147-190.

Straube J, Gorse AD, Huang BE, Lê Cao KA. A linear mixed model spline framework for analyzing time-course 'omics' data. PloS one. 2015; 10(8): e0134540.

Hinterwirth H, Stegemann C, Mayr M. Lipidomics: the quest for molecular lipid biomarkers in cardiovascular disease. Circulation: Cardiovascular Genetics. 2014; 7(6): 941-954.

Robinson JL, Nielsen J. Integrative analysis of personal omics data using biomolecular networks. Molecular BioSystems. 2016; 12(10): 2953-2964.

Wang Q, Peng WX, Wang L, Ye L. Toward multiomics-based next-generation diagnostics for precision medicine. Personalized Medicine. 2019; 16(2): 157-170.

Ovesná J, Slabý O, Toussaint O, Kodíček M, Maršík P, Pouchová V, Vaněk T. High throughput ‘omics’ approaches to assess the effects of phytochemicals in human health studies. British Journal of Nutrition. 2008; 99(E-S1): ES127-ES134.

Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007; 115(8): 1039-1050.